MAPT and Alzheimer disease: Activation or inhibition of the Hippo pathway (e.g., by pharmacological activation or CRISPR knockout) in human-derived microglial cell lines, or in control hiPSC-derived microglia, in co-culture with neurons, and measuring the resulting effect on microglial activation, Abeta/tau production, phosphorylation, and aggregation, as well as neuronal death, would be useful in defining any specific roles for microglial Hippo/YAP in some of the known pathogenic processes leading to AD.